Mohammad A. Azad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohammad A. Azad has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh N. Dave
New Jersey Center for Engineered Particulates, New Jersey Institute of Technology, Newark, NJ 07102, USA
8 shared publications - Ecevit Bilgili
Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
6 shared publications Anagha Bhakay
Otto H. York Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
3 shared publicationsAfolawemi Afolabi
Otto H. York Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
2 shared publicationsCatharina Knieke
2 shared publicationsDaniel To
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Elsevier in SSRN Electronic Journal
Direct Powder Extrusion (DPE) 3D Printing using Eudragit L100-55: Addressing Processability Challenges
Direct Powder Extrusion (DPE) 3D printing is gaining popularity in the pharmaceutical industry for its single-step, solvent-free printing process, making it ideal for personalized drug product development. This study investigates the use of Eudragit® L100-55, a pH-responsive anionic copolymer of methacrylic acid and ethyl acrylate (soluble above pH 5.5), as the primary matrix-forming polymer for fabricating a three-compartment oral dosage form via DPE 3D printing. Despite its use as an enteric polymer, Eudragit® L100-55 presents significant processing challenges for DPE due to its high molecular weight (~320,000 g/mol), elevated melt viscosity, and narrow thermal processing window, defined by a glass transition temperature (110°C) and onset of material degradation (170–200°C). To mitigate these challenges of Eudragit® L100-55, a systematic formulation strategy was employed by incorporating various functional excipients and a secondary polymer to modify the thermophysical and rheological properties of the blend. DPE 3D printing was performed using a BIO X bioprinter equipped with a thermoplastic printhead. The results demonstrate that integrating functional excipients and polymer blending significantly improved the processability of Eudragit® L100-55, making it suitable for DPE 3D printing by enabling successful printing of a 3-compartment matrix at reduced processing temperatures and pressures suitable for oral drug delivery.
- 14 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDirect Powder Extrusion (DPE) 3D Printing using Eudragit L100-55: Addressing Processability Challenges
Direct Powder Extrusion (DPE) 3D printing is gaining popularity in the pharmaceutical industry for its single-step, solvent-free printing process, making it ideal for personalized drug product development. This study investigates the use of Eudragit® L100-55, a pH-responsive anionic copolymer of methacrylic acid and ethyl acrylate (soluble above pH 5.5), as the primary matrix-forming polymer for fabricating a three-compartment oral dosage form via DPE 3D printing. Despite its use as an enteric polymer, Eudragit® L100-55 presents significant processing challenges for DPE due to its high molecular weight (~320,000 g/mol), elevated melt viscosity, and narrow thermal processing window, defined by a glass transition temperature (110°C) and onset of material degradation (170–200°C). To mitigate these challenges of Eudragit® L100-55, a systematic formulation strategy was employed by incorporating various functional excipients and a secondary polymer to modify the thermophysical and rheological properties of the blend. DPE 3D printing was performed using a BIO X bioprinter equipped with a thermoplastic printhead. The results demonstrate that integrating functional excipients and polymer blending significantly improved the processability of Eudragit® L100-55, making it suitable for DPE 3D printing by enabling successful printing of a 3-compartment matrix at reduced processing temperatures and pressures suitable for oral drug delivery.
- Open Access
- 2 June 2026
- Published by Elsevier in Bioprinting
- Vol. 58
Scaling Strategies for Bioink Manufacturing in Bone and Cartilage Bioprinting: Challenges, Innovations, and Future Perspectives
- 2 June 2026
- Published by Elsevier in Bioprinting
- Vol. 58
Open AccessScaling Strategies for Bioink Manufacturing in Bone and Cartilage Bioprinting: Challenges, Innovations, and Future Perspectives
- Open Access
- 16 December 2023
- Published by SASPR Edu International Pvt. Ltd in Journal of Advances in Education and Philosophy
- Vol. 7 (12) , 528-532
Medical Ethics and Mental Health during COVID-19
- 16 December 2023
- Published by SASPR Edu International Pvt. Ltd in Journal of Advances in Education and Philosophy
- Vol. 7 (12) , 528-532
Open AccessMedical Ethics and Mental Health during COVID-19
- 1 February 2015
- Published by Elsevier in Powder Technology
- Vol. 271, 49-60
Sub-100 micron fast dissolving nanocomposite drug powders
- 1 February 2015
- Published by Elsevier in Powder Technology
- Vol. 271, 49-60
Sub-100 micron fast dissolving nanocomposite drug powders
- 1 June 2014
- Published by Elsevier in Particuology
- Vol. 14, 76-82
Preparation of stable colloidal suspensions of superdisintegrants via wet stirred media milling
- 1 June 2014
- Published by Elsevier in Particuology
- Vol. 14, 76-82
Preparation of stable colloidal suspensions of superdisintegrants via wet stirred media milling
- 1 January 2014
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 461 (1-2) , 367-379
Redispersible fast dissolving nanocomposite microparticles of poorly water-soluble drugs
- 1 January 2014
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 461 (1-2) , 367-379
Redispersible fast dissolving nanocomposite microparticles of poorly water-soluble drugs
- 8 October 2013
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 40 (12) , 1693-1703
Preparation of concentrated stable fenofibrate suspensions via liquid antisolvent precipitation
A major challenge in achieving size stability for relatively high concentration of fine particles from poorly water-soluble drug fenofibrate (FNB) is addressed through T-mixing based liquid antisolvent precipitation in the presence of ultrasonication and judicious use of stabilizers. Multiple stabilizers were screened in a batch mode prior to their continuous formation via T-mixing. In both cases, the stable suspensions maintained their size after 2 days of storage at room temperature, with the smallest particle size of d50: ∼1.2 µm was achieved through a combination of HPMC with SDS or PF-68. The influence of processing parameters, such as sonication energy, sonication probe insert depth and solvent/antisolvent flow rate, on the particle size distribution (PSD) in T-mixing were investigated, to identify optimum processing conditions. Optimal operating and formulation conditions also allowed increase in the drug loading from 0.32% to 4% (w/v), while keeping the median size 2.5 µm. Interestingly, the primary particles observed in the SEM were spherical and under 100 nm in diameter, indicating agglomeration. It was shown that the stabilized particles could be centrifuged and did not show size growth upon resuspension, allowing for increase in the drug loading up to 27% (w/v), which is a significant novel outcome.
- 8 October 2013
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 40 (12) , 1693-1703
Preparation of concentrated stable fenofibrate suspensions via liquid antisolvent precipitation
A major challenge in achieving size stability for relatively high concentration of fine particles from poorly water-soluble drug fenofibrate (FNB) is addressed through T-mixing based liquid antisolvent precipitation in the presence of ultrasonication and judicious use of stabilizers. Multiple stabilizers were screened in a batch mode prior to their continuous formation via T-mixing. In both cases, the stable suspensions maintained their size after 2 days of storage at room temperature, with the smallest particle size of d50: ∼1.2 µm was achieved through a combination of HPMC with SDS or PF-68. The influence of processing parameters, such as sonication energy, sonication probe insert depth and solvent/antisolvent flow rate, on the particle size distribution (PSD) in T-mixing were investigated, to identify optimum processing conditions. Optimal operating and formulation conditions also allowed increase in the drug loading from 0.32% to 4% (w/v), while keeping the median size 2.5 µm. Interestingly, the primary particles observed in the SEM were spherical and under 100 nm in diameter, indicating agglomeration. It was shown that the stabilized particles could be centrifuged and did not show size growth upon resuspension, allowing for increase in the drug loading up to 27% (w/v), which is a significant novel outcome.
- 28 August 2013
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 40 (11) , 1509-1522
Enhanced recovery and dissolution of griseofulvin nanoparticles from surfactant-free nanocomposite microparticles incorporating wet-milled swellable dispersants
Nanocomposite microparticles (NCMPs) incorporating drug nanoparticles and wet-milled swellable dispersant particles were investigated as a surfactant-free drug delivery vehicle with the goal of enhancing the nanoparticle recovery and dissolution rate of poorly water-soluble drugs. Superdisintegrants were used as inexpensive, model, swellable dispersant particles by incorporating them into NCMP structure with or without wet-stirred media milling along with the drug. Suspensions of griseofulvin (GF, model drug) along with various dispersants produced by wet-milling were coated onto Pharmatose® to prepare NCMPs in a fluidized bed process. Hydroxypropyl cellulose (HPC, polymer) alone and with sodium dodecyl sulfate (SDS, surfactant) was used as base-line stabilizer/dispersant during milling. Croscarmellose sodium (CCS, superdisintegrant) and Mannitol were used as additional dispersants to prepare surfactant-free NCMPs. Nanoparticle recovery during redispersion and dissolution of the various GF-laden NCMPs were examined. Suspensions prepared by co-milling GF/HPC/CCS or milling GF/HPC/SDS were stable after 30 h of storage. After drying, due to its extensive swelling capacity, incorporation of wet-milled CCS in the NCMPs caused effective breakage of the NCMP structure and bursting of nanoparticle clusters, ultimately leading to fast recovery of the GF nanoparticles. Optimized wet co-milling and incorporation of CCS in NCMP structure led to superior dispersant performance over incorporation of unmilled CCS or physically mixed unmilled CCS with NCMPs. The enhanced redispersion correlated well with the fast GF dissolution from the NCMPs containing either CCS particles or SDS. Overall, swellable dispersant (CCS) particles, preferably in multimodal size distribution, enable a surfactant-free formulation for fast recovery/dissolution of the GF nanoparticles.
- 28 August 2013
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 40 (11) , 1509-1522
Enhanced recovery and dissolution of griseofulvin nanoparticles from surfactant-free nanocomposite microparticles incorporating wet-milled swellable dispersants
Nanocomposite microparticles (NCMPs) incorporating drug nanoparticles and wet-milled swellable dispersant particles were investigated as a surfactant-free drug delivery vehicle with the goal of enhancing the nanoparticle recovery and dissolution rate of poorly water-soluble drugs. Superdisintegrants were used as inexpensive, model, swellable dispersant particles by incorporating them into NCMP structure with or without wet-stirred media milling along with the drug. Suspensions of griseofulvin (GF, model drug) along with various dispersants produced by wet-milling were coated onto Pharmatose® to prepare NCMPs in a fluidized bed process. Hydroxypropyl cellulose (HPC, polymer) alone and with sodium dodecyl sulfate (SDS, surfactant) was used as base-line stabilizer/dispersant during milling. Croscarmellose sodium (CCS, superdisintegrant) and Mannitol were used as additional dispersants to prepare surfactant-free NCMPs. Nanoparticle recovery during redispersion and dissolution of the various GF-laden NCMPs were examined. Suspensions prepared by co-milling GF/HPC/CCS or milling GF/HPC/SDS were stable after 30 h of storage. After drying, due to its extensive swelling capacity, incorporation of wet-milled CCS in the NCMPs caused effective breakage of the NCMP structure and bursting of nanoparticle clusters, ultimately leading to fast recovery of the GF nanoparticles. Optimized wet co-milling and incorporation of CCS in NCMP structure led to superior dispersant performance over incorporation of unmilled CCS or physically mixed unmilled CCS with NCMPs. The enhanced redispersion correlated well with the fast GF dissolution from the NCMPs containing either CCS particles or SDS. Overall, swellable dispersant (CCS) particles, preferably in multimodal size distribution, enable a surfactant-free formulation for fast recovery/dissolution of the GF nanoparticles.
- 1 July 2013
- Published by Elsevier in Chemical Engineering Research and Design
- Vol. 91 (7) , 1245-1258
A study of the physical stability of wet media-milled fenofibrate suspensions using dynamic equilibrium curves
- 1 July 2013
- Published by Elsevier in Chemical Engineering Research and Design
- Vol. 91 (7) , 1245-1258
A study of the physical stability of wet media-milled fenofibrate suspensions using dynamic equilibrium curves